Methylprednisolone sodium succinate (Hospira)

Maa: Uusi-Seelanti

Kieli: englanti

Lähde: Medsafe (Medicines Safety Authority)

Aktiivinen ainesosa:

Methylprednisolone sodium succinate 1326mg equivalent to 1000 mg Methylprednisolone;  

Saatavilla:

Pfizer New Zealand Limited

INN (Kansainvälinen yleisnimi):

Methylprednisolone sodium succinate 1326 mg (Equiv to 1000 mg Methylprednisolone)

Annos:

1000 mg

Lääkemuoto:

Powder for injection

Koostumus:

Active: Methylprednisolone sodium succinate 1326mg equivalent to 1000 mg Methylprednisolone   Excipient: Dibasic sodium phosphate Monobasic sodium phosphate

Kpl paketissa:

Vial, glass, Powder, 1000 mg

luokka:

Prescription

Prescription tyyppi:

Prescription

Valmistaja:

Sicor (Societa Italiana Corticosteroidi) Srl

Tuoteyhteenveto:

Package - Contents - Shelf Life: Vial, glass, Powder - 1000 mg - 24 months from date of manufacture stored at or below 25°C

Valtuutus päivämäärä:

1990-07-02

Valmisteyhteenveto

Data Sheet – New Zealand 

Hosp 2 
                 1 

METHYLPREDNISOLONE SODIUM SUCCINATE POWDER 
FOR INJECTION 
PRESENTATION 
Methylprednisolone Sodium Succinate Powder for Injection is a
sterile lyophilised powder for injection 
containing 500 mg or 1000 mg of Methylprednisolone as the
sodium succinate.  It also contains 6.4 mg 
sodium acid phosphate and 69.8 mg sodium phosphate or 12.8 mg sodium
acid phosphate and 139.6 mg 
sodium phosphate. 

USES  
_ACTIONS _
Methylprednisolone in the form of
methylprednisolone sodium succinate is a potent synthetic 
corticosteroid.  Its anti-inflammatory potency is greater than
prednisolone in the ratio of 5 to 4.  It has only 
minimal mineralocorticoid properties and has less tendency
than prednisolone to induce sodium and 
water retention.  It influences carbohydrate, protein, fat and
purine metabolism, electrolyte and water 
balance, and the functional capacities of the
cardiovascular system, the kidney, the skeletal muscle, 
nervous system and other organs and tissues.  It exerts a
suppressive effect on the immune response. 

_PHARMACOKINETICS _
Methylprednisolone sodium succinate for injection, is rapidly and
extensively hydrolysed _in vivo _by 
cholinesterases to free methylprednisolone. 

_INDICATIONS _
Methylprednisolone sodium succinate may be used in conditions in
which a rapid, intense glucocorticoid 
effect is required. 

ENDOCRINE DISORDERS 
•  Primary or secondary adrenocortical
insufficiency (hydrocortisone or cortisone is the drug of choice; 
synthetic analogs may be used in conjunction with
mineralocorticoids where applicable; in infancy, 
mineralocorticoid supplementation is of particular importance). 
•  Acute adrenocortical insufficiency (hydrocortisone
or cortisone is the drug of choice; mineralocorticoid 
supplementation may be necessary, particularly when synthetic an